||Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy
Mariko, Ogawa-Momohara ,
Yoshinao, Muro ,
Minoru, SatohMasashi, Akiyama
307 , 2017-08 , Elsevier
Background: Anti-Su antibodies are found in 5–20% of cases of various systemic autoimmune rheumatic diseasesand in 5–10% of dermatomyositis (DM)/polymyositis (PM) patients. In 2006, the 100 kDa Su antigen wasidentified as argonaute2 (Ago2), and it was found to play a major role in RNA interference. However, immunoprecipitation(IP) remains the main method for detecting anti-Su and the clinical significance of the antibodiesis uncertain.Methods: Sera from patients with DM/PM (n = 224) were screened by an ELISA that uses recombinant biotinylatedAgo2 protein. Some serum samples were tested by IP and by indirect immunofluorescence (IIF) analysis.Results: Seventeen (7.5%, 17/224) sera from DM/PM were positive in ELISA. Of the 33 IP-tested sera (17 ELISApositiveand 16 ELISA-negative with high background), 13 were found to be anti-Ago2/Su-positive in IP andELISA. Only one IP-positive serum was judged to be ELISA-negative. Among the 13 patients with anti-Su/Ago2, 7cases also had myositis-specific autoantibodies. Six sera that were positive by both IP and ELISA showed the GWbody pattern in IIF. Interestingly, one ELISA-positive serum with an inconclusive result in IP also showed the GWbody pattern.Conclusion: Our novel ELISA appears to be useful for screening anti-Su/Ago2 antibodies (sensitivity: 93%,specificity: 79%).